This article is a Preprint
Preprints are preliminary research reports that have not been certified by peer review. They should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Preprints posted online allow authors to receive rapid feedback and the entire scientific community can appraise the work for themselves and respond appropriately. Those comments are posted alongside the preprints for anyone to read them and serve as a post publication assessment.
Dual Action Potential: Bromophenol in Combatting COVID-19 and Modulating ACE2-Mediated Circulatory Hemostasis: A Molecular Modeling Study (preprint)
researchsquare; 2024.
Preprint
in English
| PREPRINT-RESEARCHSQUARE | ID: ppzbmed-10.21203.rs.3.rs-4017904.v1
ABSTRACT
The possible recurrent threat of the COVID-19pandemic driven by SARS-CoV-2 underscores the critical need for innovative pharmaceutical interventions targeting Angiotensin-Converting Enzyme 2 (ACE2) receptors. Beyond the recognized role of ACE2in viral entry, its intricate involvement in circulatory hemostasis, with potential hypotension-related complications, necessitates a comprehensive approach. This in silico study investigates the therapeutic potential of Bromophenol (BP) derived from Halophitys incurves (HIE) against both ACE2-mediated viral entry and circulatory complications, particularly hypotension. Utilizing advanced in silico techniques; we assessed the pharmacokinetic parameters of BP through SWISSADME, ADME/T, and Swisstargetprediction. The Molecular Dynamics Simulation analysis further substantiated the favorable interactions within the BP-ACE2 complex. The results elucidated a favorable performance of BP in comparison to β-D-Mannose, serving as a potent inhibitor in impeding ACE2-mediated viral entry and contributing to the regulation of circulatory hemostasis. This inquiry emphasizes BP's potential as a robust inhibitor against the multifaceted actions of ACE2, offering valuable insights into its therapeutic effectiveness against COVID-19. Additionally, it contributes to a deeper understanding of ACE2-mediated circulatory hemostasis by revealing BP's regulatory role in this physiological process. The encouraging findings warrant further exploration of BP as a novel therapeutic agent targeting ACE2 -induced dual unfavorable actions.
Full text:
Available
Collection:
Preprints
Database:
PREPRINT-RESEARCHSQUARE
Main subject:
COVID-19
/
Hypotension
Language:
English
Year:
2024
Document Type:
Preprint
Similar
MEDLINE
...
LILACS
LIS